Clinical trials: Coronary Artery Bypass Graft
Coronary Artery Disease
Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)
The goal of this study is to assess safety and efficacy of Humacyte's coronary tissue engineered vessel (CTEV) used as a bypass conduit in patients requiring multi vessel coronary artery bypass grafting (CABG).
- Trial name
- NCT07730528
- Testing
- Humacyte Coronary Tissue Engineered Vessel (CTEV)
- Volunteers
- 10 people
- Sponsor
- Humacyte, Inc.
Coronary Artery Disease
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass…
- Trial name
- NCT00042081
- Testing
- CGT003 (E2F Duplex Decoy)
- Where
- 154 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Anesiva, Inc.
Coronary Disease
Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass
The purpose of this trial is to identify a dose or doses of INS50589 intravenous infusion that are well-tolerated and which reduce postoperative bleeding and blood product transfusion.
- Trial name
- NCT00316212
- Testing
- INS50589 Intravenous Infusion
- Where
- 27 sites in United States
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Bypass Surgery, Coronary Heart Disease
Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA
The purpose of this study is to assess the effects of nesiritide compared to placebo when given with standard of care therapies, on kidney function, heart function and the need of other treatments in heart failure patients…
- Conditions
- Coronary Artery Bypass Surgery, Coronary Heart Disease, Coronary Artery Bypass Grafting, Cardiopulmonary Bypass
- Trial name
- NCT00653042
- Testing
- Nesiritide
- Volunteers
- 305 people
- Sponsor
- Scios, Inc.
Coronary Artery Disease, Multi Vessel Coronary Artery Disease
Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass
To assess safety and feasibility of a coronary bypass created with Vascudyne Acellular Tissue Engineered Vessel (ATEV) with External Support Structure (ESS) in patients requiring multi vessel coronary artery bypass grafting…
- Trial name
- VCAB-2 (NCT07078370)
- Testing
- ATEV with ESS
- Where
- 4 sites in Poland
- Volunteers
- 20 people
- Sponsor
- Vascudyne, Inc.
Coronary Artery Disease, Coronary Arteriosclerosis
Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium
The purpose of this research study is to determine if the transplant of a combination of stem cells, obtained from the bone marrow of the same patient, is effective for utilization and rescue of infarcted myocardium.
- Conditions
- Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease
- Trial name
- NCT00548613
- Testing
- MESENDO
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- TCA Cellular Therapy
Coronary Heart Disease
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.
- Trial name
- NCT00130871
- Testing
- levosimendan
- Where
- 2 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Orion Corporation, Orion Pharma
Coronary Artery Disease
Initial Evaluation of Vascudyne Coronary Artery Bypass Conduit
The Vascudyne Coronary Artery Bypass Study (VCAB-1) is an initial safety and feasibility study of the Vascudyne, Inc. Coronary Artery Bypass Conduit (CAB A) for bypass of stenosed native coronary arteries in patients undergoing…
- Trial name
- VCAB-1 (NCT06434935)
- Testing
- CABA
- Where
- Paraguay
- Volunteers
- 5 people
- Sponsor
- Vascudyne, Inc.
Advanced Heart Failure, Ischemic Heart Failure
HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery
This clinical study will evaluate the safety and tolerability of HiCM-188, an investigational allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocyte therapy, in adults with advanced heart failure who are undergoing…
- Trial name
- NCT07646210
- Testing
- HiCM-188 Cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Cardiovascular Disease, Coronary Artery Bypass
Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)
For some people who have heart by-pass surgery, the vein that is used to by-pass a blockage will, after some time, become narrowed and possibly blocked.
- Trial name
- NCT00451256
- Testing
- AVI-5126
- Where
- Ukraine
- Volunteers
- 600 people
- Sponsor
- Sarepta Therapeutics, Inc.
Coronary Artery Disease (CAD)
Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery
Comparison of the cardioprotective effects and safety of two cardioplegic solutions (solutions used during a cardiac arrest in the heart surgery) in patients undergoing cardiopulmonary bypass for coronary artery bypass surgery.
- Trial name
- NCT01444235
- Testing
- Custodiol-N, Custodiol
- Where
- 4 sites in Germany
- Volunteers
- 102 people
- Sponsor
- Dr. F. Köhler Chemie GmbH
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
The purpose of this study is to determine whether MC-1 is effective and safe in reducing cardiovascular and neurological events in patients undergoing high-risk coronary artery bypass surgery
- Conditions
- Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
- Trial name
- NCT00157716
- Testing
- (MC-1) Pyridoxal-5'-phosphate
- Where
- 2 sites in United States, Canada
- Volunteers
- 900 people
- Sponsor
- Medicure
Bleeding, Bypass Complication
A Pre-market, Multi-center, International, Double-blind, Randomized, Two-arms, Controlled, Prospective Clinical Investigation Assessing the Safety and Performance of a Medical Device (ClearPlasma™) for the Treatment of Patients Undergoing Coronary Artery Bypass or Valve Replacement
Bleeding is a significant complication in cardiac surgery, with 10-15% of open cardiac surgery patients experiencing major intra- or post-operative bleeding.
- Conditions
- Bleeding, Bypass Complication, Valve Replacement
- Trial name
- NCT05542277
- Testing
- ClearPlasma
- Where
- 8 sites in Czechia, Israel and 1 more
- Volunteers
- 130 people
- Sponsor
- PlasFree Ltd.
Coronary Arteriosclerosis, Atrial Fibrillation
A(f)MAZE-CABG Study
Concomitant AF ablation with HIFU in patients with persistent or long standing persistent AF undergoing CABG will be superior in restoring SR, compared with patients with persistent or long standing persistent AF undergoing CABG…
- Conditions
- Coronary Arteriosclerosis, Atrial Fibrillation, Coronary Artery Bypass Graft Surgery
- Trial name
- AFMAZE-CABG (NCT00735722)
- Testing
- HIFU AF Ablation
- Where
- 10 sites in Canada, Finland and 4 more
- Volunteers
- 188 people
- Sponsor
- Abbott Medical Devices
Bloodloss, Surgical Procedures, Operative
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.
- Trial name
- CONSERV-1 (NCT00816023)
- Testing
- ecallantide
- Where
- 29 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Multi Vessel Coronary Artery Disease
Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)
A prospective, single arm, non-randomized FIH feasibility study to evaluate the preliminary safety and performance of the XABG technology in patients with multi-vessel atherosclerotic coronary artery disease, scheduled by the…
- Trial name
- XABG FIH (NCT04545112)
- Testing
- CABG
- Where
- 4 sites in Belgium, Lithuania and 1 more
- Volunteers
- 20 people
- Sponsor
- Xeltis
Atherosclerosis of Autologous Vein Coronary Artery Bypass Graft(s)
The eMESH 1 Feasibility Study
Multi-center, dual cohort (randomized and single vessel) study designed to demonstrate feasibility, initial safety and performance of the Kips Bay Medical, Inc.
- Trial name
- eMESH 1 (NCT01676376)
- Testing
- eSVS Mesh treated saphenous vein graft, Control saphenous vein graft
- Where
- 15 sites in United States, Czechia and 5 more
- Volunteers
- 120 people
- Sponsor
- Kips Bay Medical, Inc.
Aortic Valve Replacement, Coronary Artery Bypass Grafting
Hemodynamic Assessment of Mosaic Ultra Stented Heart Valve in the Aortic Position
The special fixation methodology of the Mosaic Ultra stented procine bioprosthesis allows valves to maintain their natural leaflet structure and root geometry which prevents leaflet calcification and improves hemodynamic…
- Trial name
- NCT00477555
- Testing
- Aortic implantation of Mosaic Ultra porcine bioprosthesis
- Where
- 11 sites in Austria, Belgium and 3 more
- Volunteers
- 43 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Thrombocytopenia, Thrombosis
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS)…
- Conditions
- Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
- Trial name
- NCT00073580
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- The Medicines Company
Heart Disease
Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery
This is a Phase 2, multicenter, open-label, single-arm, sequential cohort study to be conducted in up to 30 subjects. The study will evaluate subjects undergoing primary, elective, off-pump CABG surgery with median sternotomy.
- Trial name
- SNAP-CABG-OFF (NCT00808964)
- Testing
- NU172
- Volunteers
- 30 people
- Sponsor
- ARCA Biopharma, Inc.